Recent News

• 12.12.2025 - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 12.02.2025 - Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
• 11.20.2025 - Zevra Therapeutics, Inc. Announces CFO Transition
• 11.05.2025 - Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
• 10.29.2025 - Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
• 10.27.2025 - Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
• 10.06.2025 - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 12.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.09.2025 - 3 Initial statement of beneficial ownership of securities
• 12.02.2025 - 8-K Current report
• 12.02.2025 - EX-99.1 EX-99.1
• 11.20.2025 - EX-99.1 EX-99.1
• 11.20.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - 8-K Current report